Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Co. stock logo
GKOS
Glaukos
$98.94
+2.5%
$91.93
$45.38
$102.33
$4.84B1.08511,632 shs363,654 shs
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$96.38
+0.6%
$102.15
$78.28
$212.43
$2.33B0.69212,636 shs133,539 shs
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$113.62
+1.4%
$111.34
$70.24
$140.00
$3.49B1.31438,340 shs301,248 shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
Nevro Corp. stock logo
NVRO
Nevro
$12.29
+1.7%
$14.33
$11.98
$34.86
$442.74M0.89380,265 shs575,808 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Co. stock logo
GKOS
Glaukos
+2.53%+2.21%+12.33%+6.88%+99.60%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
+0.64%-0.74%-1.75%+0.64%-46.77%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
+1.36%+3.78%+4.88%-2.97%-18.67%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-7.39%
Nevro Corp. stock logo
NVRO
Nevro
+1.78%-1.64%-9.40%-34.41%-63.02%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Co. stock logo
GKOS
Glaukos
3.5358 of 5 stars
2.42.00.04.43.12.50.6
ICU Medical, Inc. stock logo
ICUI
ICU Medical
4.3675 of 5 stars
3.53.00.03.91.32.51.9
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.2839 of 5 stars
2.51.00.00.00.00.80.6
NuVasive, Inc. stock logo
NUVA
NuVasive
1.9302 of 5 stars
3.30.00.00.00.00.03.1
Nevro Corp. stock logo
NVRO
Nevro
1.592 of 5 stars
4.01.00.00.00.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Co. stock logo
GKOS
Glaukos
2.78
Moderate Buy$99.800.87% Upside
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.00
Buy$123.0027.62% Upside
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
3.00
Buy$135.1118.91% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2372.82% Upside

Current Analyst Ratings

Latest GKOS, NVRO, ICUI, IRTC, and NUVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/8/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Glaukos Co. stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
3/25/2024
Glaukos Co. stock logo
GKOS
Glaukos
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $120.00
3/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
2/28/2024
ICU Medical, Inc. stock logo
ICUI
ICU Medical
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$134.00 ➝ $136.00
2/23/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$142.00 ➝ $133.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Co. stock logo
GKOS
Glaukos
$314.71M15.78N/AN/A$9.46 per share10.46
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$2.26B1.04$15.42 per share6.25$87.96 per share1.10
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$492.68M7.18N/AN/A$6.85 per share16.59
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.06N/AN/A$8.10 per share1.52

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.78N/AN/AN/A-42.79%-22.67%-11.50%5/1/2024 (Confirmed)
ICU Medical, Inc. stock logo
ICUI
ICU Medical
-$29.66M-$1.23N/A17.91N/A-1.31%6.35%3.03%5/13/2024 (Estimated)
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$123.41M-$4.05N/AN/AN/A-25.05%-56.38%-28.63%5/2/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%5/7/2024 (Confirmed)

Latest GKOS, NVRO, ICUI, IRTC, and NUVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nevro Corp. stock logo
NVRO
Nevro
-$1.02N/A+$1.02N/AN/AN/A  
5/2/2024N/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$0.99N/A+$0.99N/AN/AN/A  
5/1/2024N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$0.59N/A+$0.59N/AN/AN/A  
2/27/2024Q4 2023
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$0.85$1.24+$0.39$3.19$564.77 million$587.86 million
2/22/2024Q4 2023
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$0.60-$1.26-$0.66-$1.26$131.14 million$132.51 million
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
N/AN/AN/AN/AN/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Co. stock logo
GKOS
Glaukos
0.77
5.34
4.78
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.74
2.53
1.06
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.17
2.15
2.02
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
96.10%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
Glaukos Co. stock logo
GKOS
Glaukos
6.40%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
6.70%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.68%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%
Nevro Corp. stock logo
NVRO
Nevro
3.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90750.19 million46.98 millionOptionable
ICU Medical, Inc. stock logo
ICUI
ICU Medical
14,00024.36 million22.73 millionOptionable
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
2,00031.12 million30.91 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable

GKOS, NVRO, ICUI, IRTC, and NUVA Headlines

SourceHeadline
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00
americanbankingnews.com - April 13 at 5:32 AM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM
Why Nevro Stock Lagged the Market on ThursdayWhy Nevro Stock Lagged the Market on Thursday
fool.com - February 22 at 6:21 PM
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 OutlookHold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
markets.businessinsider.com - February 22 at 2:16 PM
Analyst Scoreboard: 4 Ratings For NevroAnalyst Scoreboard: 4 Ratings For Nevro
markets.businessinsider.com - February 22 at 2:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
ICU Medical logo

ICU Medical

NASDAQ:ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
iRhythm Technologies logo

iRhythm Technologies

NASDAQ:IRTC
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.